Abstract
IntroductionCarvedilol reduces rates of variceal bleeding and rebleeding by lowering portal pressure. However, an associated pleotropic survival benefit has been proposed. We aim to investigate further by undertaking long-term follow-up...
Highlights
Primary sclerosing cholangitis (PSC) is a rare disorder and as such clinical care can be heterogeneous
We audited PSC management across the UK against audit standards set by the British Society of Gastroenterology (BSG)
All UK PSC investigators were invited to complete an electronic questionnaire on the PSC patient cohort encompassing demographics, diagnosis, bowel and biliary tract cancer surveillance, and risk stratification data (March 2019 - Jan 2021)
Summary
Primary sclerosing cholangitis (PSC) is a rare disorder and as such clinical care can be heterogeneous. Our aim was to compare the effectiveness of second-line therapies in primary biliary cholangitis (PBC), with regards Obeticholic acid (OCA) and non-licensed therapy (fibric acid derivatives; FA) across a nationwide cohort of patients (pts). The OCA group manifest greater ALP values at baseline than those initiating FA therapy (2.9 v 2.3 x ULN; P = 0.001), with a greater proportion being ursodeoxycholic acid non-responders (63.5% vs 45.4%; P = 0.001), cirrhotic (16.5% v 8.3%; p = 0.03), or having an abnormal bilirubin (22.1% v 12%; p = 0.02). In patients with cirrhosis under OCA treatment (n=57), significant reduction in ALP, ALT and bilirubin were observed at 12 mo (p
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
